Skip to main content

Table 1 Characteristics of the study population, overall and by seropositivity for anti-PT IgG

From: Seroprevalence of Bordetella pertussis antibodies in adults in Hungary: results of an epidemiological cross-sectional study

 

Total (n = 1999)

Seropositivea (n = 295)

Seronegativeb (n = 1704)

Demographics

 Age (years)

47.4 ± 17.7

48.8 ± 19.4

47.1 ± 17.4

 Female

1212/1999 (60.6)

160/295 (54.2)

1052/1704 (61.7)

Pertussis-related history

 Pertussis vaccination

882/1163 (75.8)

127/165 (77.0)

755/998 (75.7)

 Prior pertussis

88/1566 (5.6)

15/227 (6.6)

73/1339 (5.5)

  Infant

3/87 (3.4)

0

3/73 (4.1)

  Child

75/87 (86.2)

13/14 (92.9)

62/73 (84.9)

  Adolescent

3/87 (3.4)

1/14 (7.1)

2/73 (2.7)

  Adult

6/87 (6.9)

0

6/73 (8.2)

 Long-lasting coughc

164/1971 (8.3)

20/290 (6.9)

144/1681 (8.6)

 Recent contact with a person with pertussis/long-lasting coughc

227/1795 (12.6)

30/270 (11.1)

197/1525 (12.9)

 Regular contact with children

919/1999 (46.0)

122/295 (41.4)

797/1704 (46.8)

 Relevant medicationsd

241/1962 (12.3)

39/287 (13.6)

202/1675 (12.1)

 Relevant hospitalizationse

10/1994 (0.5)

4/294 (1.4)

6/1700 (0.4)

  1. Data are mean ± SD or n/N (%), where N is the number of subjects with known data
  2. Abbreviations: Anti-PT IgG anti-pertussis toxin immunoglobulin G, OD optical density, SD standard deviation
  3. a>0.3 OD units
  4. b≤0.3 OD units
  5. cLasting ≥3 weeks in the previous 12 months
  6. dAny antibiotics and/or other medication (i.e., any cough medicines) for lower respiratory tract infections or (suspected) pertussis infections in the previous 12 months
  7. eHospitalized due to respiratory infections in the previous 12 months